1Hoffman B B,Sharma K,Ziyadeh F N.Potemtial role of TGE beta in diabetic nephrpathiy,Miner-Electrlyte-Metab[J].Kidney Int,1998,24(2):190-196.
2[3]杨佳丽.从分子生物学角度揭示他汀类药物作用机理[N].健康报,2001-8-15(1).
3Yang T,Chen J W,Liu C P.Combination of Simvastatin and Cilazapril have prentive effect ondiabetic nephropathy in diabetic rat and cultured mesangial cell[J].Diabetologia,2001,44:265.
1Wautier MP, Chappey O, Corda S, et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab. 2001, 280: 685.
2Yim MB, Yim HS, Lee C, et al. Protein glycation: creation of catalytic sites for free radical generation. Ann N Y Acad Sci,2001,928:48.
3Chung SS, Ho EC, Lain KS, et al. Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Sue Nephrol,2003, 14: 233.
4Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hvperglycaemic damage. Nature, 2000, 404: 787.
5Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature,2001,414:813.
6Yamamoto A, Hoshi K, Ichihara K. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes. Eur J Pharmacol,1998,361:143.
7Wemer N, Niekenig G, Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitor's. Basic Res Cardiol,2002,97:105.
8Deakin S, Leviev 1, Guernier S, et al. Simvastatin modulates expression of the PONI gene and increases serum paraoxonase:a role for sterol regulatory element-binding protein-2.Arterioscler Thromb Vase Biol, 2003, 23: 2083.
9Usui H, Shikata K, Matsuda M, et al. HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats. Nephrol Dial Transplant, 2003, 18: 265.
10Khamaisi M, Kavel O, Rosenstock M, et al. Effect of inhibition of glutathione synthesis on insulin action: in vivo and in vitro studies using buthionine sulfoximine. Biochem J, 2000,349: 579.
8Alderson P, Green S, Higgins JPT. Cochrane Reviewers'Handbook 4.2.2[updated March 2004]. In: The Cochrane Library, Issue 1,2004.
9Mitch WE. Treating diabetic nephropathy--are there only economic issues? New England Journal of Medicine, 2004, 351 ( 19): 1934-1936.
10Hung CC, Yinn YG, Shyi TS, et al. Insulin and heparin suppress superoxide production in diabetic rat glomeruli stimulated with lowdensity lipoprotein. Kidney, 2001, 59(suppl): 124.
